Donald Trump tax cuts could mean more Novartis investment in US
Donald Trump`s plans to cut US corporate tax rates could trigger increased investment in the United States (US) by Novartis, its chief executive told Reuters, despite the president-elect`s recent harsh words on drug prices.
"When we build a new manufacturing site we think about the tax rate, we think about the economy of the country, we think about jobs, so a booming US economy would make the US more attractive for investment," Joe Jimenez said on Wednesday.
Trump unnerved drug company executives last week by saying the industry was "getting away with murder" on pricing and promising to introduce more competition to drive down costs.
Jimenez said on the sidelines of the World Economic Forum in Davos, Switzerland, that he expected continued pressure on prices in the US market but his company was already adapting by shifting to outcomes-based pricing.
The Swiss drugmaker recently struck deals with two US insurers for its heart failure drug Entresto under which payments are calculated based on any proven reduction in patient admissions to hospital, not on the number of pills consumed.
Entresto has got off to slow start but Jimenez said there had been a "nice pick up in prescriptions" more recently. It will update investors on prospects for the potential blockbuster when it reports full-year results next week, he added.
ALSO READ: Novartis prepares to sell Rs 91,800 crore stake in rival Roche
Novartis is holding an R&D day to coincide with its results on January 25, where it will highlight pipeline prospects.
These include a novel cell therapy for childhood leukaemia called CTL-019, which Jimenez confirmed was on track for submission to regulators for approval early this year.
Another closely watched new drug is BAF-312 for secondary progressive multiple sclerosis. Novartis is discussing with US and European regulators whether it could file BAF-312 for approval based on a single Phase III clinical trial, Jimenez said.
Novartis is looking to these and other new products for heart and eye conditions to help offset generic competition to its old blood cancer drug Glivec.
"We have a number of catalysts that are coming," Jimenez said. "From the end of 2017 we will be completely out from under that genericisation and the company should enter its next growth phase beginning in 2018."
Novartis is currently weighing plans to sell its substantial stake in Basel-based rival Roche but Jimenez said he was in no rush, adding that recent weakness in European drug stocks relative to US ones meant the timing wasn`t right just now.
"Obviously, when we move on that stake it would be at a time when we want to ensure that Novartis shareholders get the benefit of the most value," he said.
Novartis built up its one-third stake in Roche voting stock between 2001 and 2003 under former Chairman Daniel Vasella for a possible merger that never happened.
ALSO READ: Donald Trump warns US firms moving jobs offshore, singling out pharma
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Senior Citizen Latest FD Rates: Know what major banks like SBI, PNB, Canara Bank, HDFC Bank, ICICI Bank are providing on fixed deposits
Gratuity Calculator: Rs 38,000 as last-drawn basic salary, 5 years and 5 months of service; what will be gratuity amount?
Top 5 Small Cap Mutual Funds with best SIP returns in 1 year: See how Rs 25,000 monthly investment has grown in each scheme
Top 7 SBI Mutual Funds With Best SIP Returns in 1 Year: Rs 25,000 monthly SIP investment in No.1 fund has jumped to Rs 3,58,404
04:31 PM IST